🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We’re heading to the @AANMember Annual Meeting to connect with leading experts share the latest research and discuss advancements in #neurology. If you're attending #AAN2025, be sure to stop by: brnw.ch/21wRO7t #SCA #Epilepsy #Migraine #Parkinsons

In the latest episode of Global Genes RARECast, our Senior Medical Director, Melissa Beiner, M.D., talks about #spinocerebellarataxia (SCA), a rare and progressive disease that impacts movement, balance and coordination: bit.ly/446Jkyr #CareAboutRARE #RareDisease

Our team has wrapped up another successful American Academy of Neurology Annual Meeting. A huge thank you to everyone who participated and shared their insights. Check out some highlights from the event! #AAN2025 #SCA #Epilepsy #Migraine #Parkinsons

Exciting news: Biohaven has secured up to $600M in strategic #investment from Oberland Capital. This financing strengthens our mission to deliver life-changing therapies across immunology, neuroscience, and oncology. Learn more: bit.ly/3GwgjTm #InvestorNews $BHVN

Honored to learn from leading #physicians and #scientists at our recent peripartum cardiomyopathy ad board. Their insights are shaping Biohaven’s efforts to improve #cardiac outcomes for new moms. We also presented at CPPCongress last week. Learn more: bit.ly/4481iRm

Biohaven is going green for #MentalHealthAwarenessMonth. We stand with everyone affected by #mentalhealth challenges and are proud to raise awareness and show our support. #DaysMatter #MajorDepressiveDisorder #OCD

We’re joining National Ataxia Foundation in urging the FDA to take action for people living with #spinocerebellarataxia (SCA) and other rare diseases still waiting for approved therapies. This petition is a call for urgency, compassion, and change: bit.ly/3EDxdif #DaysMatter

#ICYMI: At the American Academy of Neurology Annual Meeting, Jason Lerner, MD, sat down with VJ Neurology to talk about our investigational potassium channel activator being studied for #epilepsy and #neuropsychiatricdisorders. Learn more about our study results: bit.ly/4jJslqH

We are joining the Yale Ventures Innovation Summit, featuring 40+ panels across #biotech, #health, #neuroscience and more. A global gathering of leaders and entrepreneurs shaping the future. Registration is now open: brnw.ch/21wSLaK #YaleInnovation25

Professor Jonathan Barratt from University of Leicester shares why he’s excited about our extracellular #degrader technology and its potential to transform treatment for IgA nephropathy by targeting the root cause while sparing the rest of the #immune system. #IgANephropathy #MedEd

We shared early clinical data at our Research and Development Day showing encouraging results from our next-generation #ADC programs. Our first-in-class FGFR3-directed ADC has also entered the clinic: bit.ly/4joA2C2 #MedEd #MedX

Congrats to Gene Dubowchik, Ph.D., our SVP of Molecular Technologies, on being elected to the CT Academy of Science and Engineering! This honor highlights Gene’s leadership and lasting impact on science and innovation in Connecticut. #CASE2025 #STEM

We’ve enrolled the first patient in our Phase 2/3 #clinicaltrial of a first-in-class, oral, brain-penetrant TYK2/JAK1 inhibitor for early #ParkinsonsDisease. This novel therapy targets neuroinflammation and immune dysregulation driving disease progression: brnw.ch/21wT9mk

At #AAN2025, Volkan Granit, MD, MSc, our Medical Director of Clinical Development, sat down with VJ Neurology to discuss our investigational TRPM3 antagonist and its potential role in treating pain. View the full interview: bit.ly/3RSVPGO #PainResearch #DaysMatter

We’re teaming up with Bexorg Inc., using their human brain and #AI system to advance how we study neuro treatments. Featured in Endpoints News, this approach helps us better assess drug activity and biomarkers earlier in development. Read more: bit.ly/3ZoDipS

Our Executive Medical Director, Bharat Awsare, MD, shares his view on precision medicine’s future in Pharmaceutical Executive highlighting a shift to targeting root causes, not just symptoms. Read more: bit.ly/4kzeNPq #PrecisionMedicine

Check out our feature in Ataxia UK’s magazine after a visit to their London office. In a Q&A, our Rare Disease Marketing, Patient Advocacy and Engagement Lead shares how meeting the #SCA community deepens our purpose and drives our research forward: bit.ly/3SKehBN

In a guest column in Cell&Gene, Melissa Beiner, MD, our Senior Medical Director, highlights the physical, emotional and socioeconomic impact of spinocerebellar ataxia (SCA), emphasizing the need for greater awareness, research and regulatory support: bit.ly/3TCnE6T

Events like the Annual SMA Conference continue to emphasize to our team that patients and families are counting on us. We are leaving this Cure SMA #conference feeling more inspired than ever to help people living with #SMA. #spinalmuscularatrophy

Happy Independence Day from Biohaven! Wishing all a relaxing and safe holiday. #FourthOfJuly #IndependenceDay 🇺🇸